Pds biotech provides business update and reports second quarter 2021 financial results

Florham park, n.j., aug. 12, 2021 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies based on the company's proprietary versamune® t-cell activating technology, will discuss its financial results for the quarter ended june 30, 2021 and provide a business update on its conference call today.
PDSB Ratings Summary
PDSB Quant Ranking